Canada markets closed

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.48+0.02 (+0.31%)
At close: 4:00PM EST
Sign in to post a message.
  • t
    the
    My take on the unjustified drop on SLDB’s stock price tonight after hours. Shortly before market closed, Srpt, a competitor of Sldb announced that their “gene therapy failed to separate from placebo on primary functional endpoint.” This means that there was no difference between people who received their gene therapy and those who did not but were told that they did (placebo). Someone mistakenly and wrongfully thinking it was bad news for Sldb as it is in the same sector dumped a huge amount of shares of Sldb around 400 k after hours which squeezed the price downward. In fact this is wrong because if Hertz goes bankrupt, Avis gains. Moreover, Sldb’s gene therapy utilizes a different mechanism than that of srpt. Consequently, I believe it is positive news and tomorrow Sldb should and will rise on the news of Srpt’s (hertz) failures as it is Avis in this case.
  • D
    DrrJohn
    Sareptas srp-9001 contains the central H2 hinge region which has been associated with structurally altered "inferior" ring myofibers. This might explain the lack of clinical efficacy despite a significant rise in microdystrophin.
    Neither Solid's SGT-001 (nor do I believe Pfizers microdystrophin candidate) contain H2 . Moreover, SGT-001contains the R16/17 NOS domain, which has been linked to better (muscle) exercise tolerance.
    Therefore, Sareptas failure does not necessarily translate into failure of Solids candidate.
    Dr John

    PS: Don't own SRPT, SLBD, or PFE
  • m
    metoo
    Solid Biosciences upgraded to Neutral on Sarepta setback at Credit Suisse Credit Suisse analyst Martin Auster upgraded Solid Biosciences (SLDB) to Neutral from Underperform with a price target of $7, up from $2. The setback by competitor Sarepta Therapeutics (SRPT) in Duchenne muscular dystrophy gene therapy program creates "optionality" for Solid, Auster tells investors in a research note. With the competitive landscape now altered, if Solid's SGT-001 "defied long odds and succeeds clinically," there is a much greater peak share opportunity for the asset, says the analyst.
  • D
    Deliverancebanjoboy
    SRPT news. Good for the entire sector. I added at 6.19.
  • D
    Deliverancebanjoboy
    Thursday's presentation should be a great risk/reward event. Seems to me they already factored in a SRPT comparison to SLDB's drug. If the company can differentiate their product from SRPTs we will have a good response in the market.
  • O
    One of few words
    What happened to Sarepta stock price is proof that there is very little surety that any biotech will be successful right up to the very end - if you are going to invest in this sector, you need to have multiple stocks.... the good news is that you may only need one or two of these to get great returns......high risk, high reward.
  • D
    DM
    Based on the data it appears the younger cohort did better for Sarepta's microdys...hoping but my bet is on Solid at the moment...hopeful enrollment will no longer be an issue and given the protocol amendment with less weight individuals/younger my hope is Solid efficacy may prove to be successful for the patients. Good luck and with the drop after hours may allow for entry for many.
  • O
    Ofelia
    what is going on?
  • m
    metoo
    Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference Thursday, January 14, 2021
  • d
    david
    SRPT was overvalued anyway I sold mine at 90 years ago..don't sell sldb is my course here
  • R
    Rodney
    Hey shorty sorry did you feel that SQUEEEZE today. I know I did and it felt GOOOOD. Thank you from the bottom of my bottle of Krystal :-)
  • R
    Rodney
    Ameritrade mistakenly put in news that SLDB missed its endpoint not SRPT
  • S
    Syndergaard
    Signed up to (http://Rightpicker.com) last month and instantly saw why my trading buddy has been banking so many winners. She tried to fly under the radar but the secret is out. Join them today.
  • c
    cheryl
    SRPT is a 13 Billion dollar company this is $500 Million...there's really only 2 plays in DMD therapy..this is a great value considering 2 years ago traded around $30 a share
  • D
    Deliverancebanjoboy
    Downgrade or offering??
  • Y
    Yahoo Finance Insights
    Solid Biosciences reached a 52 Week high at 8.34
  • B
    Billy
    unusually lage upside option activity at 10 bucks, don't give your shares away on the cheap, restarting of trial will likely boost share price
  • V
    Viresh
    Solid Bioscience will get a court case for inside knowledge and inside trading. only started selling in after hours
  • B
    Billy
    @david,,aren't you glad you sold, too funny
  • m
    metoo
    Some of top biotech hedge funds acquired shares from its $90M private share offering.

    RA Capital disclosed it acquired 5.4M+ shs at $3.7/sh and raised its stake to ~10M or 11.8% of O/S.👇🏿

    The buyers yet to disclose:
    Perceptive
    EcoR1
    Boxer
    Suvretta